International Cancer Cluster Showcase 2022

Digital Brochure - Launched June 13, 2022

International Cancer Cluster Showcase 2022

Organizers

Cambridge Innovation Partners

MONTRÉAL INVIVO

THE WISTAR INSTITUTE

OSLO CANCER CLUSTER

obn

biopôle

MATWIN
MATURATION & ACCELERATING TRANSLATION WITH INDUSTRY

Digital Brochure - Launched June 13, 2022

The International Cancer Cluster Showcase (ICCS) 2022 features 21 emerging oncology companies from the United States (Massachusetts & Philadelphia), Quebec, Norway, the UK Golden Triangle, Switzerland, and France.

Learn more about these oncology companies, their technologies and assets in this Digital Brochure. May you discover novel collaboration and investment opportunities during your digital journey to our seven innovation hubs. Utilize this opportunity to reach out to them for an introductory meeting.

If you are interested in a particular company and would like to learn more about other innovations emerging in the partner regions, contact the organizing partners as entry points for accessing the regional and national innovation milieus.

Thank you for joining ICCS 2022.
We look forward to hearing from you and welcome!

The Organizing Partners

About ICCS and BIO. Over 200 representatives from the international oncology community have joined and actively participated at ICCS each year since 2012. ICCS has traditionally been a satellite event to BIO where partners team up to highlight recent innovations from their regions. This year ICCS is presented via this digital brochure.

ICCS 2023 will be planned as an on-site event in Boston, where ICCS started in 2012.

Headlines ICCS 2022

Cell- and Gene Therapy

Page 04

- Jentera Therapeutics
- Kargenera
- Modulari-T Biosciences
- MPC Therapeutics
- Smart Immune
- Tigen Pharma

Immuno-Oncology

Page 06

- EverImmune
- Epitopea
- Hubro Therapeutics
- InsideOutBio
- Pilatus Biosciences
- Salubris Biotherapeutics
- SFA Therapeutics

Targeted Treatments

Page 09

- Antikor Biopharma
- EpiGenOnco
- Oxford Target Therapeutics
- SynDevRx
- Thelper
- TheraPPI Bioscience

Diagnostics and Digital Solutions

Page 11

- DoMore Diagnostics
- Miso Chip

Cell- and Gene Therapy

JENTHERA THERAPEUTICS

Presented by Montréal InVivo

- Company | Jenthera Therapeutics inc.
- Contact | Laurent D. Ziri, Chief Operating Officer
- Email | laurent.ziri@jenthera.com
- Website | www.jenthera.com

Jenthera is a preclinical biotech leveraging a novel non-viral and non-lipid CRISPR platform directly delivering the CRISPR protein for the development of groundbreaking therapeutics. The platform addresses the critical limitations of CRISPR developments: precision, safety, and cost of therapies and features unprecedented precision and correction capacities (over 90% HDR), proposing to unlock new realms of possibilities in gene editing. In-vivo data strongly supports our approach as we currently collaborate with high profile academic and industry partners towards partnerships focusing on B-ALL leukemia, KRAS oncogene targeting and cell therapies. We look to secure additional partners and/or funding for the expansion of pipeline opportunities.

Presented by OBN

- Company | Kargenera
- Contact | Jim Millen, Director
- Email | jmillen@kargenera.com
- Website | *under development*

Cancer remains one of the top causes of death in developed countries and current immune approaches to therapy are expensive and have met with mixed results.

NK cells represent the latest frontier in the use of immune therapies to fight cancer. Research (published in Science Immunology) has led to the identification and patenting of NK-cell stimulatory receptors and activating peptides delivered using a simple nucleotide technology platform. Lead asset KG001 benefits from comprehensive pre-clinical data demonstrating efficacy both alone and in combination with anti-PDL1. Advised by experts from industry and academia, the company is seeking £3.5M seed funding to reach CTA/ IND.

Presented by Montréal InVivo

- Company | Modulari-T Biosciences
- Contact | David White, CEO
- Email | david@modularit.bio
- Website | www.modularit.bio

Cell and gene therapy promises to one day cure any pathology; Modulari-T's MARC Platform produces the tools to fulfill that promise. The MARCs or Modular Actuation Receptor Complex are a new modality of receptor design to address the shortcomings of CAR-T therapy. MARCs recreate the natural architecture of immune receptor to increase treatment potency 2-fold and persistence 5-fold versus CAR-T.

Modulari-T is a preclinical stage company building the world's most powerful receptor platform for cell therapy. We offer our platform as a service to partners looking to develop targeted cell therapies for oncology. We can support or take on the design of tailor-made receptors for any cell type from conception to preclinical validation.

Cell- and Gene Therapy

MPC Therapeutics

Presented by MATWIN

- Company | MPC Therapeutics
- Contact | Raphael Martinou, CEO
- Email | Raphael.martinou@mpc-therapeutics.com
- Website | www.therapeutics.com

CAR-T therapy has revolutionized cancer treatment, but many challenges remain to unlock its full potential. Recent literature supports the importance of "Stem Cell Memory T cells (TSCM)" to increase the anti-tumor response and long-term persistence in patients. The Swiss biotech company MPC Therapeutics has developed a small molecule, MITO-66, that inhibits the Mitochondrial Pyruvate Carrier (MPC) and triggers the proliferation of TSCM. Used during the manufacturing of CAR T cells, MITO-66 induces a durable metabolic reprogramming which leads to fitter mitochondria and an increased pool of TSCM. They have recently shown that MITO-66 conditioning enables CAR T cells to cure 100% of mice with human leukemia and drastically improves anti-tumor effects in hard-to-treat solid tumors. They are looking to partner with a CAR T manufacturer seeking to improve the performance of its T cell therapies.

smart immune

Presented by MATWIN

- Company | Smart Immune
- Contact | Karine Rossignol, CEO
- Email | karine.rossignol@smart-immune.com
- Website | www.smart-immune.com

Smart Immune is a French clinical-stage biotechnology company that has developed a new generation of T cell medicine focused on a thymus-based cell and gene therapy platform called ProTcellTM. The ProTcell platform aims to overcome the limitations of allogeneic CAR-T cells: GvHD and short persistence. In allo-HSCT setting, ProTcell strives to accelerate immune reconstitution and fight relapses and infections. The platform differentiates HSCs form healthy donors into T cell progenitors in 7 days only versus 12 months in Human Physiology. When infused, those cells are educated by the Thymus into fully functional T cell. When transduced with CAR, they have high potential for persistence thanks to thymic education.

Smart Immune has three ongoing clinical trials and plans to initiate a € 50M euros fundraising in Sept 2022 while seeking partnerships for their CAR ProTcell applications.

TIGEN

Presented by Biopôle

- Company | Tigen Pharma SA
- Contact | Emmanuel Savioz, CEO
- Email | emmanuel.savioz@tigenpharma.com
- Website | www.tigenpharma.com

We are a Swiss biotech company in the field of cell therapies to cure cancer. We are a disruptive catalyst, combining a unique culture with a multidisciplinary set of world-class capabilities and a long-term perspective to the benefit of patients and society. We bridge the gap between academic ideas and commercial applications by combining state-of-the-art process development, equipment and analytics around T cell-based therapies. Our pipeline and our manufacturing platform provide an end-to-end solution and will accelerate the development and access to novel therapies. We are shaping a disruptive ecosystem in the CGT field and are looking to collaborate with all stakeholders in the system. From academic centers to biotech and pharma companies, CMOs, health authorities, insurances, patient organizations, hospitals, investors, and other interest groups.

Immuno-Oncology

Presented by MATWIN

- Company | EverImmune
- Contact | Jean-Luc Marsat, President
- Email | jeanluc.marsat@everimmune.com
- Website | www.everimmune.net

Immune checkpoint blockers (ICB) offer more durable responses and fewer side effects than chemotherapy. In Non-small cell lung cancer (NSCLC) and Renal cell carcinoma (RCC), the failure rate of ICBs is above 60%. The cost of ineffective immunotherapy per year in these indications ranges between 1,4bM€ in EU5 and 2,2b€ in USA. Oncobax® AK is composed of a specific strain of Akkermansia for oral administration to be used as an adjuvant of cancer immunotherapy in patients with NSCLC & RCC resistant to ICBs lacking Akkermansia. The therapeutic goal is to induce tumor response in at least 20% of resistant patients with a patent-protected product. EverImmune aims to license Oncobax® AK in 2024 after completing a phase 2, in NSCLC and RCC cancers. Complementary R&D efforts are ongoing to demonstrate anti-cancer benefits of Oncobax® AK in other indications. Fundings for Oncobax® AK or other products in the pipeline are proposed.

Presented by OBN

- Company | Epitopea Ltd
- Contact | Jon Moore, CEO
- Email | jon.moore@epitopea.com
- Website | www.epitopea.com

At Epitopea, we believe better cancer therapies are needed to transform patients' lives. Our technology platform builds on a proprietary and innovative approach to identifying shared, aberrantly expressed tumour-specific antigens, known as CryptigenTM TSAs, licensed from the Université de Montréal; We have already secured a £10 million Seed Round and will use these funds to deliver development candidates representing accessible off-the-shelf immunotherapeutics that can deliver durable benefits;

We are interested in meeting:

- investors for discussions about participating in a future Series A round;
- companies with vaccine platforms;
- pharma companies interested in early-stage partnerships to accelerate the exploitation of CryptigenTM TSAs in additional cancers.

Presented by Oslo Cancer Cluster

- Company | Hubro Therapeutics
- Contact | Jon Amund Eriksen, CEO
- Email | jon.amund.eriksen@hubrotherapeutics.com
- Website | www.hubrotherapeutics.com

Despite recent progress of new cancer therapies, there is still an unmet need for effective cancer treatments. Hubro's proprietary peptide vaccines target tumor specific neoantigens resulting from microsatellite instability (MSI) and frameshift mutation. Our vaccines have both therapeutic and prophylactic potential. The lead candidate vaccine FMPV-1 targets frameshift mutation of TGFbR2 present in about 80% of MSI colorectal and gastric cancers as well as in 90% of hereditary colon cancer. A Phase 1 study with FMPV-1 has been conducted in healthy volunteers and FMPV-1 is ready for clinical Phase 2 development. We are also developing a diagnostic for detection of frameshift mutations in liquid biopsies. Hubro Therapeutics is supported by the Norwegian Research Council and are currently looking for funding and partners for the further development of our technologies.

Immuno-Oncology

inside out bio
science for living well

Presented by Cambridge Innovation Partners

- Company | InsideOutBio
- Contact | Alan Herbert, President and CSO
- Email | alan.herbert@insideoutbio.com
- Website | www.Insideoutbio.com

InsideOutBio is targeting breast and pancreatic tumors that are unresponsive to current immunotherapies. The company has a unique, validated and peer-reviewed mechanism of action with proof of principle for oral delivery of medicine. InsideOutBio is currently seeking funding in order to screen for lead compounds and build their intellectual property portfolio. The company is also seeking additional team members, including a CEO.

Pilatus Biosciences

Presented by Biopôle

- Company | Pilatus Biosciences SA
- Contact | Hung-Kai Chen, CEO
- Email | hkchen@pilatusbio.com
- Website | *under development*

Metabolic stress in tumors can be very debilitating to immune cells, attenuating their ability to attack the cancer. Immunometabolism-mediated mechanisms of tumor resistance are major barriers to more effective cancer immunotherapy. Co-Founded and led by a pioneer in immunometabolism, Professor Ping-Chih Ho of the Ludwig Institute for Cancer Research, we are on a mission to develop next-generation therapeutics that target metabolic checkpoints. We are developing an antibody that prevents lipid transport by CD36, which is expressed on tumor-resident regulatory T cells and has been linked to T cell dysfunction. Our CD36 antibody reduces adverse metabolic effects and allows tumor control in animal models. A second asset is a bifunctional protein being developed to reactivate terminally-exhausted T cells. We are seeking Series A funds to support IND-enabling studies.

SalubrisBio

Presented by Cambridge Innovation Partners

- Company | Salubris Biotherapeutics Inc.
- Contact | Sam Murphy, CEO
- Email | sam.murphy@salubrisbio.com
- Website | www.salubrisbio.com

JK08 is a recombinant fusion protein consisting of a CTLA-4-specific antibody and an IL-15 fusion domain. A breadth of clinical studies with CTLA-4 antibodies and recombinant IL-15 portend synergistic effects in an antibody fusion construct. Ipilimumab validated CTLA-4 as a target for cancer therapy, but response rates are limited. Clinical sample analysis demonstrated NK cell activity signatures and ADCC biomarkers correlate with ipilimumab responses. Recombinant IL-15 has exhibited potent stimulation of NK cell expansion and enhancement of ADCC in pre-clinical and clinical studies. Through molecular integration of a CTLA-4 antibody and IL-15, JK08 can channel the potent immune stimulation of IL-15 through the CTLA-4 antibody domain towards depletion of T-regulatory cells and targeted reversal of immunosuppression which may contribute to cancer progression.

Immuno-Oncology

Presented by The Wistar Institute

- Company | SFA Therapeutics
- Contact | Ira C. Spector, CEO and Co-Founder
- Email | info@sfatherapeutics.com
- Website | https://sfatherapeutics.com/

SFA Therapeutics, Inc. is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment of chronic inflammatory disease and cancer – the use of microbiome-derived metabolites as drugs. Our microbiome-derived drugs are derived from natural substances, and enable a new platform for developing treatments which have the potential to treat over 85 chronic inflammatory diseases currently afflicting patients; providing safer treatments than current therapies. Our pipeline includes treatments for Liver Cancer (Hepatitis B, NASH and HCC), Psoriasis, Ophthalmic Diseases, Cytokine Release Syndrome- a side effect in CAR-T, Prevention of Relapse/ Recurrence in Leukemias, and other diseases. We deploy a completely new approach to drug discovery and development.

Targeted Treatments

ANTIKOR
INNOVATION IN ADCs

Presented by OBN

- Company | Antikor Biopharma Ltd
- Contact | Mahendra Deonarain, CEO
- Email | m.deonarain@antikor.co.uk
- Website | www.antikor.co.uk

There are limited treatment options for solid tumors, especially the difficult ones like colon, gastric and pancreatic. Many of the targeted therapies that work well in breast or urological cancer do not have the same outcomes in gastrointestinal cancers. We need drugs tailored for solid tumor penetration, a key barrier in addressing such diseases. Antikor has taken the established area of Antibody Drug Conjugates (ADCs) and innovated to create Antibody Fragment Drug Conjugates (FDCs), which penetrate solid tumors more rapidly/effectively and deliver more cytotoxic payload. Antikor have a preclinical lead product, ANT-045 which has proof-of-concept data in tumor models, a good safety profile in rodents and is superior to the current benchmark ADC. Antikor is looking for development partners and investment to take ANT-045 into the clinic.

EPIGEN ONCO

Presented by The Wistar Institute

- Company | EpiGenOnco, LLC
- Contact | Jean-Pierre Issa, President and CSO
- Email | info@epigenonco.com
- Website | www.epigenonco.com

EpiGenOnco, LLC is a biopharmaceutical company, headquartered in Philadelphia, dedicated to the discovery and development of a new treatment for cancer based on reprogramming the epigenome. With more than two decades of experience elucidating the function of epigenetic regulators, we are utilizing proprietary epigenetic screening tools to identify and validate new small molecules that selectively target the epigenetic activity of CDK9 to kill cancer cells and make refractory cancer cells sensitive to new treatments.

xford Target Therapeutics

Presented by OBN

- Company | Oxford Target Therapeutics
- Contact | Natalie Curtis, CEO
- Email | nataliecurtis95@gmail.com
- Website | www.oxfordtargettherapeutics.com

Treatment for triple negative breast cancer (TNBC) is especially challenging with current options of limited effectiveness.

Oxford Target Therapeutics have developed a platform technology of a novel class of small molecules that inhibit TNBC cell proliferation. Strong in vitro and preliminary in vivo data shows our innovation satisfies key pharmacological parameters, with a PCT patent filed. Due to the underlying mechanism of action, our technology is applicable to other types of cancer and animal tumors and anticipated to less likely lead to side effects and drug resistance.

We seek R&D collaborations, business partnerships, investors, and funding to help grow our commercial offering and develop our technology into clinical candidates.

Targeted Treatments

The Metabo-Oncology Company™

Presented by Cambridge Innovation Partners

- Company | SynDevRx, Inc.
- Contact | James Shanahan, Co-Founder, CBO
- Email | jshanahan@syndevrx.com
- Website | www.syndevrx.com

SynDevRx is developing treatments that address the negative effects of dysregulated metabolic hormones on cancer growth and metastases, an emerging field of research known as metabo-oncology. SynDevRx lead drug candidate evexomostat (SDX-7320) is in Phase 2 clinical studies for breast cancer to determine whether improving hormones, together with the drug's effects on angiogenesis and the tumor micro-environment, will result in better outcomes for cancer patients.

SynDevRx is looking to work with pharma and biotech partners as well as institutional investors to continue clinical development of evexomostat.

THELPER Cellular Therapies

Presented by Oslo Cancer Cluster

- Company | Thelper AS
- Contact | Katja Vetvik, CEO
- Email | katja@thelper.com
- Website | *under development*

Thelper AS is a discovery stage company developing immunotherapies against novel, highly expressed viral targets in aggressive cancers with limited therapeutic options, such as triple negative breast cancer and glioblastoma. These viral targets are not encoded in human DNA and normally absent in healthy human cells and tissues, suggesting likely favorable toxicity profiles and therapeutic indices with targeted therapy. We currently have 4 candidates in our pipeline that each target specific, well defined viral epitopes. Our lead candidate is a bispecific T cell engager that is presently being evaluated for its cytotoxicity profile. We are looking to build relationships with potential funding partners for our future clinical studies.

---

theraPPI

Presented by Biopôle

- Company | TheraPPI Bioscience
- Contact | Luc Otten, CEO
- Email | luc.otten@tppibio.com
- Website | www.tppibio.com

The prognosis of patients with advanced cancers remains poor and too many patients with rare diseases cannot be cured. TheraPPI creates drugs that modify protein interactions to provide superior efficacy and safety. TheraPPI develops its first program against drug-resistant cancers. Targeting a novel protein-protein interaction, the program has shown reduced cancer resistance, efficacy in mouse models and increased synergy with immunotherapies. TheraPPI plans to enter into clinical development in less than 2 years.

TheraPPI is a non-integrated biotech company and aims to develop a portfolio of in-house generated drugs against advanced cancers and rare diseases. TheraPPI is currently seeking financing to further advance its ambitious program.

Diagnostics and Digital Solutions

DoMore DIAGNOSTICS

Presented by Oslo Cancer Cluster

- Company | DoMore Diagnostics
- Contact | Torbjørn Furuseth, CEO and Co-founder
- Email | torbjorn.furuseth@domorediagnostics.com
- Website | www.domorediagnostics.com

Prediction of patient outcomes in cancer is essential to personalize treatment and increase the likelihood of success in drug development. Despite decades with significant efforts in gene sequencing, there is a large medical need for better cancer markers.

Digital pathology and deep learning are on the verge of a breakthrough in medicine and can meet this need for high value markers. DoMore Diagnostics is uniquely positioned with IP protected and scalable technology based on top notch research (published in The Lancet – Deep learning for prediction of colorectal cancer outcome) and being the first company to obtain CE Mark for a prognostic digital marker. We are looking for investors that can bring relevant expertise and network to the company, and partners that can take our products into clinical use or pharma drug development.

MISO CHIP

Presented by Montréal InVivo

- Company | MISO Chip
- Contact | Etienne Laurent, Co-Founder, VP Product
- Email | elaurent@misochip.com
- Website | www.misochip.com

MISO Chip is developing a novel diagnostic platform to help oncologists personalize cancer treatment. The tumor explant platform allows the test of a treatment on tumor sample ex vivo in order to have a preview of its efficacy before treatment has started. Today, MISO Chip offers contract-research services helping biotechs de-risk their clinical trials by testing their drugs on patient tumor samples. Compelling proof-of-concepts are published in peer-reviewed articles and a pilot clinical trial using the patented technology showed promising results for predicting patient response. Now, MISO Chip is raising CA$ 2M for its seed round to support commercialization of its preclinical services and to develop its first diagnostic test.

Partner Profiles and Contact

Cambridge Innovation Partners

Cambridge Innovation Partners is a consulting firm based in Cambridge, Massachusetts, that helps innovative startups find global and local resources for success. The firm offers emerging companies experienced and professional assistance to: develop and refine investment pitches; develop strategic business plans; identify most suitable launch markets; and to locate further sources of expertise (technical, legal, and managerial) able to provide effective, practical input. Cambridge Innovation Partners also supports the development of regional tech ecosystems to encourage, establish, and expand science- and tech-based companies.

In particular, Cambridge Innovation Partners has extensive expertise in a large range of programs which universities (and other research institutions) have developed to commercialize innovations and to support spin-off companies.

- Company | Cambridge Innovation Partners
- Contact | Abigail Barrow, Christa Bleyleben
- Email | abarrow@cambridgeinno.com, cbleyleben@massglobalpartners.com
- Website | www.cambridgeinno.com

Montréal InVivo

Montréal InVivo, Québec, assumes a unifying leadership of all actors, whether they are organizations, institutions or companies working in this sector of Greater Montreal. We make sure to work with all stakeholders to strengthen the growth and competitiveness of the Life Science and Health Technology (LSHT) sector. We are known for our mobilizing force, our voice as a privileged independent interlocutor for the public sector as well as our ability to initiate and lead structuring projects for the development of the sector. Montréal InVivo is a credible source of information and the reference for the LSHT sector.

- Company | Montréal InVivo
- Contact | Farah Bendahmane
- Email | fbendahmane@montreal-invivo.com
- Website | www.montreal-invivo.com

The Wistar Institute

The Wistar Institute, Philadelphia, is the nation's first independent institution devoted to medical research and training. The Wistar Institute has evolved from its beginnings as an anatomical teaching museum to its present-day status as an international leader in basic biomedical research.

In 1972, The Wistar Institute was designated a National Cancer Institute Cancer Center in basic research, a distinction it holds to this day. Wistar discoveries have led to the development of vaccines for rabies, rubella, and rotavirus, the identification of genes associated with breast, lung, and prostate cancer, and the development of monoclonal antibodies and other significant research technologies and tools.

- Company | The Wistar Institute
- Contact | Heather A. Steinman
- Email | hsteinman@wistar.org
- Website | www.wistar.org

Partner Profiles and Contact

OSLO CANCER CLUSTER

Oslo Cancer Cluster is an oncology research and industry cluster dedicated to improving the lives of cancer patients by accelerating the development of new cancer diagnostics and treatment. Organized as national non-profit member organization, the nearly 100 members represent the entire value chain including academic research institutes, university hospitals, start-ups, biotechs, international Pharma companies and investors. The cluster is advancing a growing pipeline of preclinical and clinical stage assets with strength in cancer immunotherapy and precision medicine with several companies being collocated in the Oslo Cancer Cluster Innovation Park and Incubator.

- Company | Oslo Cancer Cluster
- Contact | Jutta Heix
- Email | jh@oslocancercluster.no
- Website | www.oslocancercluster.no

obn

OBN is the UK's largest and most innovative not-for-profit R&D membership organisation for Life Sciences with over 400-member companies, ranging from start-ups through to unicorns and Big Pharma, and is the most national of all the UK membership groups.

Our goal is to create and develop an environment that nurtures the emergence and growth of innovative and successful Life Sciences companies and new products / services by providing unrivalled opportunities for networking, partnering, purchasing, training, advising and advocacy activities. OBN's four distinct and differentiated flagship events (BioTrinity, BioForward BioSeed, & OBN Awards) are a series of major events where each satisfies a specific need but together address all the various & critical requirements of the life sciences sector.

- Company | OBN
- Contact | Jonathan Rohll
- Email | jonathan.rohll@obn.org.uk
- Website | www.obn.org.uk

biopôle

Biopôle Lausanne is one of the largest life science campuses in Europe, hosting a vibrant community of world-renowned industry players and research institutes. Biopôle is located in Lausanne (Switzerland), at the heart of the Swiss Health Valley. It provides a world-class combination of modern infrastructure (up to 134,000 sqm/1,440,000 sqft of office and laboratory space), added value services, extensive networking opportunities and unparalleled community engagement where companies can thrive and bring science to life. Today, Biopôle houses more than 120 companies and organizations, 25 world-famous research groups, a life science incubator (StartLab) a new concept of "Ready-to-move-in serviced laboratories (Superlab), a hub dedicated to Digital Health, a Start-Up fund, enabling outstanding innovation for the betterment of healthcare.

- Company | Biopôle
- Contact | Olivier Philippe
- Email | olivier.philippe@biopole.ch
- Website | www.biopole.ch

Partner Profiles and Contact

MATWIN is a French open-innovation platform strictly dedicated to the support of innovation in oncology. Our main goal is to help European scientists and entrepreneurs evaluate and optimize opportunities to transform their research into product through the access to a support program to help fast-track projects developing oncology products or solutions.

The MATWIN accelerator program is supported by an ongoing partnership with major international companies involved in oncology: Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, MSD, Nanostring Technologies, Novartis, Pfizer, Pierre Fabre, Roche & Sanofi, looking forward optimizing partnership opportunities.

MATWIN also organises each year a European Partnering convention called www.MEET2WIN fully dedicated to open innovation in oncology. Each year the convention unites nearly 300 european participants (international companies, biotechs, startups, researchers, investors, etc.) and generates more than 1,500 B2B meetings to increase collaboration opportunities in the field.

Finally, MATWIN is also coordinator of the www.OncoSTART consortium bringing together 12 key national players in oncology research and innovation willing to support entrepreneurship in the fight against cancer.

- Company | MATWIN
- Contact | Lucia Robert
- Email | lucia.robert@matwin.fr
- Website | www.matwin.fr